These result categories distinguish whether tumor cells show a receptor signal, lack the marker, or produce it at unusually high levels. The distinction helps characterize the tumor and can inform prognosis estimation and biomarker-driven treatment selection. Because receptor expression can vary among tumor types, interpretation depends on which marker is being assessed and the cancer context.
These approaches examine receptor-related features through different laboratory readouts. Immunohistochemistry detects receptor proteins in tumor tissue, whereas fluorescence in situ hybridization and other molecular assays provide information related to gene activity. Using an appropriate assay helps laboratories determine whether a relevant marker is present, absent, or overexpressed, supporting more complete tumor characterization.
Receptor relevance is not identical across tumors, so laboratories assess markers appropriate to the disease being studied. In breast cancer, estrogen receptors, progesterone receptors, and HER2 are commonly examined, while other tumor types may require different markers. This disease-specific strategy makes the result more useful for classification, prognosis estimation, and treatment planning.
A typical workflow begins with tumor tissue, followed by an assay that detects receptor proteins or gene activity. The laboratory then evaluates the finding as receptor presence, absence, or overexpression and relates it to the tumor’s characteristics. This sequence converts a tissue measurement into information that can support classification and biomarker-guided decisions.
It is most useful when a receptor serves as a biomarker linked to therapeutic decision-making. The laboratory result can indicate whether a tumor expresses a relevant target and therefore help inform biomarker-driven therapy selection. It also contributes to tumor classification and prognosis estimation, giving researchers and clinical teams molecular information beyond general tumor description.
Repeated or comparative receptor measurements can help researchers examine how tumors relate to treatment response and why resistance may emerge. Differences in receptor status can also reveal heterogeneity, meaning molecular variation within or among tumor samples. These observations support studies of changing tumor biology and help investigate why biomarker-guided treatment outcomes may differ between cancers.